| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7799897 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jun, 2022
(1 year, 10 months ago) | |
| US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(3 years from now) | |
| US10011637 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8637451 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Mar, 2022
(2 years ago) | |
| US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(7 years from now) | |
| US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(7 years from now) | |
| US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(7 years from now) | |
| US11319346 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Mar, 2032
(7 years from now) | |
| US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(8 years from now) | |
| US11142549 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(10 years from now) | |
| US11834521 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(10 years from now) | |
Trulance is owned by Salix.
Trulance contains Plecanatide.
Trulance has a total of 11 drug patents out of which 2 drug patents have expired.
Expired drug patents of Trulance are:
- US8637451
- US7799897
Trulance was authorised for market use on 19 January, 2017.
Trulance is available in tablet;oral dosage forms.
Trulance can be used as elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit, chronic idiopathic constipation, irritable bowel syndrome with constipation.
Drug patent challenges can be filed against Trulance from 19 January, 2021.
The generics of Trulance are possible to be released after 05 June, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2022 |
| New Indication(I-764) | Jan 24, 2021 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 19 January, 2021
Market Authorisation Date: 19 January, 2017
Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Irritable bowel syndrome with constipation; Chronic idiopathic constipation
Dosage: TABLET;ORAL
TRULANCE family patents
